Combined use of intranasal Dexmedetomidine and an oral novel formulation of Midazolam for sedation of young children during brain MRI examination: a prospective, single-center, randomized controlled trial

Table 7 Comparison of abnormal heart rate occurrence between group A and B

Group	n=	Abnormal HR(n=)	Abnormal MAP (n=)	Occurrence of abnormal HR (%)	Occurrence of abnormal MAP (%)
A	77	12	8	15.58	10.39
B	79	10	5	12.66	6.33
χ²				0.276	0.842
p				0.6	0.359

HR heart rate, MAP mean arterial pressure
Note: All enumeration data were expressed as numbers or percentages. groups A: 3 ug/kg intranasal DEX plus 0.2 mg/kg oral Midazolam solution (2 mg/ml); group B: 2 ug/kg intranasal DEX plus 0.2 mg/kg oral Midazolam solution (2 mg/ml).

ISSN: 1471-2253